keyword
MENU ▼
Read by QxMD icon Read
search

muscle invasive urothelial bladder cancer

keyword
https://www.readbyqxmd.com/read/28344356/methylation-status-as-a-predictor-of-intravesical-bacillus-calmette-gu%C3%A3-rin-bcg-immunotherapy-response-of-high-grade-non-muscle-invasive-bladder-tumor
#1
Petr Husek, Jaroslav Pacovsky, Marcela Chmelarova, Miroslav Podhola, Milos Brodak
BACKGROUND AND AIMS: Genetic and epigenetic alterations play an important role in urothelial cancer pathogenesis. Deeper understanding of these processes could help us achieve better diagnosis and management of this life-threatening disease. The aim of this research was to evaluate the methylation status of selected tumor suppressor genes for predicting BCG response in patients with high grade non-muscle-invasive bladder tumor (NMIBC). MATERIALS AND METHODS: We retrospectively evaluated 82 patients with high grade non-muscle-invasive bladder tumor (stage Ta, T1, CIS) who had undergone BCG instillation therapy...
March 22, 2017: Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia
https://www.readbyqxmd.com/read/28334788/impact-of-divergent-differentiation-in-urothelial-carcinoma-on-oncological-outcome-in-patients-with-t1-high-grade-bladder-cancer
#2
Nakanori Fujii, Yoshinobu Hoshii, Hiroshi Hirata, Junichi Mori, Kosuke Shimizu, Keita Kobayashi, Yoshihisa Kawai, Ryo Inoue, Yoshiaki Yamamoto, Hiroaki Matsumoto, Kazuhiro Nagao, Hideyasu Matsuyama
Objective: T1 high-grade bladder cancer has a poor prognosis compared with other non-muscle-invasive bladder cancers. We investigated the clinical outcomes among patients with T1 high-grade bladder cancer to identify factors related to cancer recurrence and disease progression. Methods: We retrospectively reviewed the data of 148 patients who were diagnosed with T1 high-grade bladder cancer by transurethral resection from January 2001 to February 2015 at our institution...
March 8, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28333021/a-phase-1-2-trial-of-a-combination-of-paclitaxel-and-trastuzumab-with-daily-irradiation-or-paclitaxel-alone-with-daily-irradiation-after-transurethral-surgery-for-noncystectomy-candidates-with-muscle-invasive-bladder-cancer-trial-nrg-oncology-rtog-0524
#3
M Dror Michaelson, Chen Hu, Huong T Pham, Douglas M Dahl, Chin Lee-Wu, Gregory P Swanson, Jacqueline Vuky, R Jeffrey Lee, Luis Souhami, Brian Chang, Asha George, Howard Sandler, William Shipley
PURPOSE: Bladder preservation therapy is an effective treatment for muscle-invasive urothelial carcinoma (UC). In this study we treated noncystectomy candidates with daily radiation and weekly paclitaxel for 7 weeks. Patients whose tumors showed her2/neu overexpression were additionally treated with weekly trastuzumab. METHODS AND MATERIALS: Sixty-eight evaluable patients were treated with radiation therapy and either paclitaxel + trastuzumab (group 1) or paclitaxel alone (group 2)...
April 1, 2017: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/28327458/nfatc1-expression-as-a-prognosticator-in-urothelial-carcinoma-of-the-upper-urinary-tract
#4
Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima, Hiroki Ide, Seiji Yamaguchi, Hiroaki Fushimi, Norio Nonomura, Hiroshi Miyamoto
We recently found that NFATc1, a member of the NFAT family and a key regulator of the immune response, could induce bladder carcinogenesis and cancer progression. In this study, we immunohistochemically stained for NFATc1 in upper urinary tract urothelial carcinoma (UUTUC) specimens and paired nonneoplastic urothelial tissues. NFATc1 was positive in 51 [52%; 40 (40%) weak (1+), 9 (9%) moderate (2+), and 2 (2%) strong (3+)] of 99 UUTUCs, which was significantly higher than in benign urothelium [30 (36%) of 83; 28 (34%) weak and 2 (2%) moderate] (0 vs 1+/2+/3+, P=...
March 16, 2017: Translational Oncology
https://www.readbyqxmd.com/read/28319171/a-reported-20-gene-expression-signature-to-predict-lymph-node-positive-disease-at-radical-cystectomy-for-muscle-invasive-bladder-cancer-is-clinically-not-applicable
#5
Kim E M van Kessel, Harmen J G van de Werken, Irene Lurkin, Angelique C J Ziel-van der Made, Ellen C Zwarthoff, Joost L Boormans
BACKGROUND: Neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) provides a small but significant survival benefit. Nevertheless, controversies on applying NAC remain because the limited benefit must be weight against chemotherapy-related toxicity and the delay of definitive local treatment. Therefore, there is a clear clinical need for tools to guide treatment decisions on NAC in MIBC. Here, we aimed to validate a previously reported 20-gene expression signature that predicted lymph node-positive disease at radical cystectomy in clinically node-negative MIBC patients, which would be a justification for upfront chemotherapy...
2017: PloS One
https://www.readbyqxmd.com/read/28314306/expression-of-indoleamine-2-3-dioxygenase-gene-is-a-feature-of-poorly-differentiated-non-muscle-invasive-urothelial-cell-bladder-carcinomas
#6
Tvrtko Hudolin, Chantal Mengus, Julie Coulot, Zeljko Kastelan, Ahmad El-Saleh, Giulio C Spagnoli
AIM: To evaluate indoleamine 2,3-dioxygenase (IDO) gene expression in non-muscle-invasive urothelial cell bladder carcinoma (NMIBC). PATIENTS AND METHODS: Seventy-four patients undergoing surgical treatment for NMIBC were enrolled in the study. IDO gene expression was assessed by quantitative real-time polymerase chain reaction (qRT-PCR). RESULTS: IDO gene expression was detectable significantly more frequently (48/74, 64.86% vs. 5/21, 23...
March 2017: Anticancer Research
https://www.readbyqxmd.com/read/28293425/podocalyxin-like-and-rna-binding-motif-protein-3-are-prognostic-biomarkers-in-urothelial-bladder-cancer-a-validatory-study
#7
Karolina Boman, Gustav Andersson, Christoffer Wennersten, Björn Nodin, Göran Ahlgren, Karin Jirström
BACKGROUND: Urothelial bladder cancer (UBC) is a disease that often is discovered when the tumour is non-muscle invasive, i.e. in Ta or T1 stage. Some patients will progress into muscle-invasive disease, a potentially deadly condition. Although there are some prognostic models, the need for prognostic and predictive biomarkers is considerate and urgent. Membranous expression of podocalyxin-like protein 1 (PODXL) and low expression of the RNA-binding motif 3 (RBM3) has previously been shown to be associated with an aggressive tumour phenotype and poor prognosis in several forms of cancer, including UBC...
2017: Biomarker Research
https://www.readbyqxmd.com/read/28291636/correlation-between-messenger-rna-expression-and-protein-expression-of-immune-checkpoint-associated-molecules-in-bladder-urothelial-carcinoma-a-retrospective-study
#8
Constance Le Goux, Diane Damotte, Sophie Vacher, Mathilde Sibony, Nicolas Barry Delongchamps, Anne Schnitzler, Benoit Terris, Marc Zerbib, Ivan Bieche, Géraldine Pignot
OBJECTIVES: Immunotherapy for bladder cancer seems to have promising results. Here, we evaluated the association between messenger RNA (mRNA) and protein levels and possible prognostic value of the programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4) immune checkpoint pathways during bladder carcinogenesis. METHODS AND MATERIALS: Tumor samples were obtained from 155 patients (84 with muscle-invasive bladder cancer [MIBC], and 71 non-muscle-invasive bladder cancer [NMIBC]) and normal bladder tissue from 15 patients...
March 10, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28280928/urothelial-carcinoma-in-first-histological-diagnosis-of-patients-over-80%C3%A2-years-has-distinctive-histological-features-a-retrospective-single-institution-study-of-185-patients
#9
Adeline Furudoï, Justine Varinot, Véronique Phe, Morgan Roupret, Marc-Olivier Bitker, Eva Compérat
Few histological data are known about patients with a first diagnosis of bladder cancer (BC) at the age ≥80 years. We describe the largest series in this patient group and their distinctive histological features. This unicentric retrospective study included patients at the age ≥80 years with a first diagnosis of bladder cancer between 2005 and 2015. All diagnosis was made by one senior uropathologist according to the WHO 2016 classification, pTNM 7th edition 2009. We examined samples of 185 patients, sex ratio M:W = 2...
March 9, 2017: Virchows Archiv: An International Journal of Pathology
https://www.readbyqxmd.com/read/28274590/role-of-inflammation-in-the-perioperative-management-of-urothelial-bladder-cancer-with-squamous-cell-features-impact-of-neutrophil-to-lymphocyte-ratio-on-outcomes-and-response-to-neoadjuvant-chemotherapy
#10
Oscar Buisan, Anna Orsola, Mario Oliveira, Roberto Martinez, Olatz Etxaniz, Joan Areal, Luis Ibarz
BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR) might reflect an increased neutrophilic inflammatory response, and urothelial tumors with squamous-cell features (SqD) have been linked to inflammation. We hypothesized that NLR could be prognostic in these patients. PATIENTS AND METHODS: In patients with SqD muscle-invasive bladder cancer treated with curative intent, NLR and relationships with outcomes were analyzed by Cox regression, log-rank, and Kaplan-Meier analysis...
February 6, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28218662/microrna-expression-profile-identifies-high-grade-non-muscle-invasive-bladder-tumors-at-elevated-risk-to-progress-to-an-invasive-phenotype
#11
Sara M Lenherr, Sheaumei Tsai, Brasil Silva Neto, Travis B Sullivan, Cara B Cimmino, Tanya Logvinenko, Jason Gee, Wei Huang, John A Libertino, Ian C Summerhayes, Kimberly M Rieger-Christ
The objective of this study was to identify a panel of microRNAs (miRNAs) differentially expressed in high-grade non-muscle invasive (NMI; TaG3-T1G3) urothelial carcinoma that progress to muscle-invasive disease compared to those that remain non-muscle invasive, whether recurrence happens or not. Eighty-nine high-grade NMI urothelial carcinoma lesions were identified and total RNA was extracted from paraffin-embedded tissue. Patients were categorized as either having a non-muscle invasive lesion with no evidence of progression over a 3-year period or as having a similar lesion showing progression to muscle invasion over the same period...
February 17, 2017: Genes
https://www.readbyqxmd.com/read/28210516/immunohistochemical-investigation-of-her-akt-mtor-pathway-and-cellular-adhesion-molecules-in-urothelial-carcinomas
#12
Nikolaos Koletsas, Triantafyllia Koletsa, Spyros Choidas, Konstantinos Anagnostopoulos, Stavros Touloupidis, Thomas Zaramboukas, Georgia Raptou, Nikolaos Papadopoulos, Maria Lambropoulou
Background. Several investigators have suggested the possibility that the expression of both EGFR and HER2 could be utilized for molecularly targeted therapy in urinary bladder cancer. We tried to evaluate the expression of HER2 and EGFR and activation of the AKT/PTEN/mTOR pathway in urothelial carcinomas and if there is any association between them and cellular adhesion molecules (CAMs). Materials and Methods. Forty-one paraffin-embedded urothelial cancer tissue blocks were collected. Immunostains for HER2, EGFR, MIB1, phospho-AKT, PTEN, phospho-mTOR, e-cadherin, p-cadherin, and b-catenin were performed on tissue microarrays sections...
2017: Pathology Research International
https://www.readbyqxmd.com/read/28197393/preclinical-efficacy-and-safety-of-the-ty21a-vaccine-strain-for-intravesical-immunotherapy-of-non-muscle-invasive-bladder-cancer
#13
Sonia Domingos-Pereira, Valérie Cesson, Mathieu F Chevalier, Laurent Derré, Patrice Jichlinski, Denise Nardelli-Haefliger
Intravesical Bacillus-Calmette-Guérin (BCG) immunotherapy can reduce recurrence/progression of non-muscle-invasive bladder cancer (NMIBC), although significant adverse events and treatment failure argue for alternative options. Here, we examined whether another attenuated live vaccine, Vivotif/Ty21a, used since more than 30 y against typhoid fever, may be safely used intravesically to improve bladder-tumor treatment. Mice-bearing MB49 orthotopic bladder-tumors treated with intravesical Ty21a or BCG were compared for survival and bacteria recovery...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28195647/molecular-classification-of-urothelial-carcinoma-global-mrna-classification-versus-tumour-cell-phenotype-classification
#14
Gottfrid Sjödahl, Pontus Eriksson, Fredrik Liedberg, Mattias Höglund
Global mRNA expression analysis is efficient for phenotypic profiling of tumours and has been used to define molecular subtypes for almost every major tumour type. A key limitation is that most tumours are communities of both tumour and non-tumour cells. This problem is particularly pertinent when analysing advanced invasive tumours, known to induce major changes and responses in both the tumour and the surrounding tissue. To identify bladder cancer tumour-cell phenotypes and compare classification by tumour-cell phenotype with classification by global gene expression analysis, we analysed 307 advanced bladder cancers (cystectomised) both by genome gene expression analysis and by immunohistochemistry using antibodies for 28 proteins...
February 13, 2017: Journal of Pathology
https://www.readbyqxmd.com/read/28163086/long-term-survival-outcomes-with-intravesical-nanoparticle-albumin-bound-paclitaxel-for-recurrent-nonmuscle-invasive-bladder-cancer-after-previous-bacillus-calmette-gu%C3%A3-rin-therapy
#15
Dennis J Robins, Wilson Sui, Justin T Matulay, Rashed Ghandour, Christopher B Anderson, G Joel DeCastro, James M McKiernan, John K Lattimer
OBJECTIVE: To report long-term follow up results of a phase II trial of salvage intravesical nanoparticle albumin bound (nab)-paclitaxel for patients with recurrent non-muscle invasive bladder cancer after previous intravesical Bacillus Calmette-Guérin (BCG) therapy. METHODS: This was a phase II trial investigating the use of intravesical nab-paclitaxel in patients with recurrent Tis, Ta, and T1 urothelial carcinoma who failed at least one prior induction course of intravesical BCG...
February 2, 2017: Urology
https://www.readbyqxmd.com/read/28134806/systemic-immunotherapy-for-urothelial-cancer-current-trends-and-future-directions
#16
REVIEW
Shilpa Gupta, David Gill, Austin Poole, Neeraj Agarwal
Urothelial cancer of the bladder, renal pelvis, ureter, and other urinary organs is the fifth most common cancer in the United States, and systemic platinum-based chemotherapy remains the standard of care for first-line treatment of advanced/metastatic urothelial carcinoma (UC). Until recently, there were very limited options for patients who are refractory to chemotherapy, or do not tolerate chemotherapy due to toxicities and overall outcomes have remained very poor. While the role of immunotherapy was first established in non-muscle invasive bladder cancer in the 1970s, no systemic immunotherapy was approved for advanced disease until the recent approval of a programmed death ligand-1 (PD-L1) inhibitor, atezolizumab, in patients with advanced/metastatic UC who have progressed on platinum-containing regimens...
January 27, 2017: Cancers
https://www.readbyqxmd.com/read/28122346/setd6-regulates-nf-%C3%AE%C2%BAb-signaling-in-urothelial-cell-survival-implications-for-bladder-cancer
#17
Neelam Mukherjee, Eduardo Cardenas, Roble Bedolla, Rita Ghosh
Non-muscle invasive bladder cancer has a high recurrence rate of 45-70%, progressing to muscle invasive disease in about 15% of those patients over a 5-year period. Administration of the mycobacterium, Bacillus Calmette-Guerin (BCG) that induces local inflammation resulting in tumor remission in responsive patients is frequently used for treatment. BCG-treated patients with NF-κB del/del genotype have an increased risk of recurrence suggesting an important role of NF-κB in bladder cancer. Since protein methyltransferases play critical roles in modulating chromatin structure and gene expression, we screened a focused array of epigenetic modification genes to identify differential expression between normal urothelial and bladder cancer cells...
January 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/28113097/the-immune-infiltrate-in-prostate-bladder-and-testicular-tumors-an-old-friend-for-new-challenges
#18
REVIEW
Cinzia Solinas, Nieves Martinez Chanzá, Ahmad Awada, Mario Scartozzi
In genito-urinary tumors immunotherapy has been administered for a long time: Calmette-Guèrin Bacillus as adjuvant treatment in high risk patients with non muscle invasive urothelial bladder cancer and interleukin-2 and interferon-α in metastatic kidney cancer. The vaccine Sipuleucel-T has been approved by United States Food and Drug Administration for the treatment of castration resistant prostate cancer patients with asymptomatic or minimally symptomatic disease, given the 22% reduction of mortality risk in this group...
February 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28106542/urinary-nid2-and-twist1-methylation-to-augment-conventional-urine-cytology-for-the-detection-of-bladder-cancer
#19
Joseph J Fantony, Thomas A Longo, Ajay Gopalakrishna, Richmond Owusu, Raymond S Lance, Wen-Chi Foo, Brant A Inman, Michael R Abern
BACKGROUND: Abnormal methylation of urinary TWIST1 and NID2 conferred high sensitivity and specificity for the detection of urothelial carcinoma. OBJECTIVE: We examine the performance of the urine-based TWIST1/NID2 methylation assay with the addition of urine cytology for the detection of urothelial carcinoma. MATERIALS AND METHODS: A prospective multi-institutional study was conducted to assess the performance of a methylation assay for patients with hematuria or under surveillance for non-muscle invasive bladder cancer (NMIBC)...
January 13, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28101348/evans-blue-mediated-white-light-detection-of-non-muscle-invasive-bladder-cancer-a-preclinical-feasibility-and-safety-study-using-a-rat-bladder-urothelial-cell-carcinoma-model
#20
Sanne Elsen, Evelyne Lerut, Frank Van Der Aa, Ben Van Cleynenbreugel, Hendrik Van Poppel, Peter De Witte
Photodynamic diagnosis (PDD) improves the detection of non-muscle-invasive bladder cancer (NMIBC). However, white-light (WL) cystoscopy remains the technique routinely used in urological clinics. A more cost-effective but equally performant alternative to PDD may encompass the use of an intense tumoritropic dye in combination with WL cystoscopy. Using a preclinical setting, we investigated the practical aspects of the use of Evans blue (EB) dye for the possible future detection of NMIBC using WL cystoscopy...
December 2016: Molecular and Clinical Oncology
keyword
keyword
105932
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"